Melatonin Bioavailability After Oral Administration of a New Delayed-Release Form in Healthy Male Volunteers [0.03%]
一种新型缓释褪黑素制剂的口服生物利用度试验
Samira Ait Abdellah,Caroline Gal,Isabelle Guinobert et al.
Samira Ait Abdellah et al.
Background: Two main types of galenic formulation, immediate release and prolonged release, have been developed to optimize melatonin bioavailability. We recently described the kinetic profile of a prolonged-release form ...
Clinical Trial
Drugs in R&D. 2024 Sep;24(3):415-423. DOI:10.1007/s40268-024-00482-6 2024
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review [0.03%]
巴氯酚佩格洛：治疗甲型血友病的新PEG修饰重组长效第八因子类产品评审报告
Mark T Reding,Shadan Lalezari,Gili Kenet et al.
Mark T Reding et al.
Damoctocog alfa pegol (BAY 94-9027, Jivi®), is a site-specifically PEGylated, extended half-life recombinant factor VIII (FVIII) that is approved in several European and non-European countries for on-demand treatment and prophylaxis of ble...
Preclinical and Toxicology Assessment of ALW-II-41-27, an Inhibitor of the Eph Receptor A2 (EphA2) [0.03%]
抗Eph受体A2（EphA2）抑制剂ALW-II-41-27的药理及毒性评估研究
Theodore J Kottom,Kimberly E Stelzig,Madeline R Pellegrino et al.
Theodore J Kottom et al.
Background and objective: The EphA2 receptor inhibitor ALW-II-41-27 has proven to be an effective in vitro antagonist of Pneumocystis β-glucan-induced proinflammatory signaling. This suggests its potential as a candidate...
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment [0.03%]
慢性肾病或肝功能障碍受试者中埃斯美他朵的药代动力学、耐受性和安全性
Nicola Ferri,Sara De Martin,James Stuart et al.
Nicola Ferri et al.
Background and objectives: Esmethadone (dextromethadone; d-methadone; S-methadone (+)-methadone; REL-1017) is a low potency N-methyl-D-aspartate (NMDA) receptor channel blocker that showed a rapid and sustained adjunctive...
Bioequivalence and Safety of Bilastine 20 mg Orodispersible Tablets and Conventional Tablets: A Randomized, Single-Dose, Two-Period Crossover Study in Healthy Volunteers Under Fasting Conditions [0.03%]
一项在空腹健康受试者中进行的单剂量、两周期交叉试验：评估比拉斯汀口腔速崩片和普通片的生物等效性和安全性（20 mg）
Manuel Román,Dolores Ochoa,Samuel Martin et al.
Manuel Román et al.
Background and objective: Orodispersible tablets (ODT) rapidly dissolve in the oral cavity and can improve patient's convenience. This pharmacokinetic study assessed the bioequivalence of a novel 20 mg ODT formulation of ...
Clinical Trial
Drugs in R&D. 2024 Sep;24(3):405-414. DOI:10.1007/s40268-024-00480-8 2024
Pharmacokinetic Bioequivalence and Safety Assessment of Two Venlafaxine Hydrochloride Extended-Release Capsules in Healthy Chinese Subjects Under Fed Conditions: A Randomized, Open-Label, Single-Dose, Crossover Study [0.03%]
在健康中国受试者餐后条件下文拉法辛缓释胶囊的人体生物等效性及安全性评价：一项随机、开放、单剂量、双周期交叉试验
Yingxia He,Jie Wang,Fang Yao et al.
Yingxia He et al.
Background and objective: Venlafaxine hydrochloride extended-release (ER) capsules are commonly used to treat depression and anxiety disorders. Evaluation of the bioequivalence of generic formulations with reference produ...
Randomized Controlled Trial
Drugs in R&D. 2024 Jun;24(2):275-283. DOI:10.1007/s40268-024-00470-w 2024
Understanding Drug Exposure and Trichuris trichiura Cure Rates: A Pharmacometric Approach for Albendazole-Ivermectin Co-medication in Tanzania and Côte d'Ivoire [0.03%]
albendazole-ivermectin联合用药治疗 Tanzania 和Côte d'Ivoire的Trichuris trichiura感染：基于药理模型的理解
Veshni Pillay-Fuentes Lorente,Jacinta N Nwogu-Attah,Britta Steffens et al.
Veshni Pillay-Fuentes Lorente et al.
Background and objective: Trichuriasis caused by the human whipworm Trichuris trichiura poses a significant public health concern. Albendazole-ivermectin co-medication is currently the most effective treatment. Studies co...
Randomized Controlled Trial
Drugs in R&D. 2024 Jun;24(2):331-340. DOI:10.1007/s40268-024-00476-4 2024
The Importance of Patient Reported Outcomes in Oncology Clinical Trials and Clinical Practice to Inform Regulatory and Healthcare Decision-Making [0.03%]
患者报告结果在肿瘤临床试验和临床实践中的重要性——对监管和卫生决策的启示
Stefania Bellino,Anna La Salvia
Stefania Bellino
Acetylsalicylic Acid with Ascorbate: A Promising Combination Therapy for Solid Tumors [0.03%]
乙酰水杨酸与抗坏血酸：实体瘤的一种前景广阔的联合疗法
Nada M El Ezaby,Entsar A Saad,Mohamed A El Basuni
Nada M El Ezaby
Background and objective: Cancer is a deadly disease with high mortality rates in developing countries. A recent preclinical study found promising results in treating hepatocellular carcinoma (HCC) by combining acetylsali...
Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis [0.03%]
与其它酪氨酸激酶抑制剂候选药物治疗多发性硬化症相比，托法替定治疗多发性硬化症的比较中枢神经系统药理学研究
Timothy J Turner,Pricilla Brun,Ross C Gruber et al.
Timothy J Turner et al.
Background and objectives: Tolebrutinib is a covalent BTK inhibitor designed and selected for potency and CNS exposure to optimize impact on BTK-dependent signaling in CNS-resident cells. We applied a translational approa...